Ethical Use of AI in Clinical Research Designing and Starting Clinical Trials

AI is transforming clinical research. Uncertainty is holding many professionals back.

Should you use AI in clinical trial operations? Can AI be trusted with sensitive research information? Will regulators accept AI-assisted workflows? And while you are working through those questions, are your colleagues already learning how to use it?

This book was written for the clinical research professional who is curious about AI but has not yet found a practical, trustworthy way to start.

What this book gives you

26 ready-to-use AI use cases across the four activities that define the start of any clinical trial: protocol design and scientific planning, site selection and investigator strategy, patient recruitment and engagement, and informed consent.

Every use case includes a prompt you can adapt immediately, an annotated example showing exactly what AI produced and what the human reviewer changed, and a clear statement of which tasks must never be delegated to AI. Because knowing where the line is matters as much as knowing what is possible.

What you will be able to do

Reduce the time to produce a protocol consistency check from a day to 20 minutes. Build a site feasibility questionnaire that asks the questions that actually predict site performance. Generate recruitment materials written at the reading level your patients can actually understand. Produce a consent form that a reviewer would be proud of and a patient can actually read.

The compliance question

This is not a book about replacing clinical judgment with AI. Every use case maps to a tier - GREEN for tasks where public AI tools are appropriate, AMBER for tasks requiring enterprise tools and qualified sign-off. The framework is specific enough to use on Monday morning and robust enough to defend to an inspector.

AI will not replace clinical research professionals who understand how to use it. But the professionals who learn to work with AI effectively - knowing what it can accelerate, what it cannot touch, and how to verify what it produces - will do better work in less time.

The CLARITY trial

Every example runs through a single fictional Phase 3 programme: the CLARITY study at ACME Biopharma, a JAK1/JAK3 inhibitor for ulcerative colitis, 260 subjects across 18 international sites. Real enough to be useful. Fictional enough to be freely shared.

Book 1 of a 4-part series covering the full drug development lifecycle. Each book stands alone.